The Right Drug Dose Now Act directs the federal government to modernize how the healthcare system uses pharmacogenomic testing—genetic tests that predict how patients will respond to medications—to prevent dangerous drug reactions. The bill requires the Department of Health and Human Services to update its national adverse drug event prevention plan to incorporate advances in genetic testing technology and research, then issue guidance to doctors, pharmacists, nurses, and other healthcare providers on when and how to use these tests. The legislation also mandates improvements to electronic health records systems so that doctors receive automatic alerts about potential drug-gene interactions before prescribing medications, and it requires updates to the FDA's drug safety reporting system to better track adverse events linked to genetic factors. Key timelines include a 180-day deadline for an initial progress report on the updated national action plan and a one-year deadline for reporting on improvements to the FDA reporting system. The bill does not appear to specify dedicated funding amounts.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.